

# Neuro-Modulation in Epilepsy

Dileep R. Nair, MD



Cleveland Clinic



# Disclosures

## Grant/Research Support:

- NIH RO1 (RO1NS089212) A Brain Atlas for Mapping Connectivity in Focal Epilepsy
- NIH RO1 (RNS097719A) Nomogram to Predict Seizure Outcome
- NeuroPace Long term Treatment Trial
- NeuroPace Post Approval Study
- Brain Sentinel

## Speaker's Bureau:

NeuroPace, Inc.

## Consultant:


NeuroPace, Inc.

## Major Shareholder:

None



# Development & Evolution of Anti-Seizure Medications




# ILAE Definition of Drug-Resistant Epilepsy

- The failure **of two appropriately chosen and tolerated AEDs** (whether as monotherapies or in combination) to control seizures when used for an adequate period of time
- Defining the terms
  - **Appropriateness:**
    - Treatment should be proven (ideally in an RCT) to be **effective** for the patient's epilepsy and seizure type
    - Treatment used at **adequate strength/dosage** for a **sufficient length of time**
  - **Tolerability:**
    - Failure can not be assumed by tolerability by itself
  - **Seizure outcome:**
    - Categorized as seizure free, treatment failure, or undetermined
    - No seizures including auras for at least three times the longest pre-intervention inter-seizure interval or 12 months or longer, with any other outcome considered a treatment failure

# Seizure Free Rates Antiepileptic Drug Regimens

- 63% remained seizure-free
- Seizure-free rates:
  - Similar between those treated with single older antiepileptic drug (67%) and those treated with a newer antiepileptic drug (69%)




Previously Untreated Patients  
(n = 470)







# Pre-surgical Evaluation

Epilepsy Center



MRI Scan



# Epilepsy Surgery

## Indications


- Medical intractability
- Tailored to the individual
- Concordance
  - Discrete MRI lesion
  - EEG and semiology
- Lack of concordance
  - More sophisticated pre-op testing
    - Ictal SPECT/PET/MEG
    - VBM/qPET
    - SEEG/Subdural/Depth

## Contra-Indications


- Multiple seizure foci
- Poor localization
- Epileptic focus overlaps with eloquent cortex
- Medical conditions affecting tolerability of surgery

# Cleveland Clinic Epilepsy Center 2017 Patient Management Discussions and Decisions

- 606 Total EMU Admissions
  - 52 patient with multiple admissions
- 15 patient admitted who passed away



**Total = 548 – 3 patient presented twice**



***Of 214 patients with surgical recommendations: 105 underwent either a resective or ablative surgery***

# Neuro-modulation in Epilepsy

- Vagus Nerve Stimulation
- Responsive Neurostimulation
- Deep Brain Stimulation



# Neuromodulation

\* FDA Approved Devices

## Targets for Stimulation

- Cerebellum
- Hippocampus
- Subthalamic Nucleus
- Caudate Nucleus
- CentroMedian Nucleus
- Anterior Nucleus of the Thalamus\*
- Various individualized cortical sites\*
- Vagus Nerve\*
- Trigeminal Nerve (External)

## Types of Stimulation

- Open Loop vs Closed Loop
- Electrical vs Magnetic
- Invasive vs Noninvasive

## Safety of Stimulation

- Electrical stimulation of brain tissue
  - Less than  $30\mu\text{C}/\text{cm}^2/\text{phase}$

# Neuro-Modulation

## **Versus Medicine/Surgery**

- Lack typical systemic or neurological sided effects
- Stimulation related side effects
  - Intracranial stimulation
  - VNS stimulation
- Surgically implanted
  - Surgical complications
  - Battery replacement
  - Less invasive
  - Reversible

## **Versus Medicine/Surgery**

- Improvement of efficacy over time

# Comparators: VNS, DBS & RNS


## Similarities

- Parameters of Stimulation
  - Anode/Cathode contacts
  - Stimulation Frequency
  - Stimulation Duration
  - Stimulation Intensity
  - Stimulation Field
  - Pulse Duration

## Differences


- Open vs Closed Loop
  - VNS (open) – heart rate feature
  - DBS (open)
  - RNS (closed)
- Magnets
  - Initiates stimulation –VNS
  - Initiates a storage of ECoG – RNS
- Stimulation
  - Determined by detection of ECoG pattern – RNS
  - Determined by ON time- VNS & DBS
- Placement of electrodes and device

# Responsive Neural Stimulation (RNS)



# Responsive Neural Stimulation

- Medically refractory focal epilepsy
  - 18 years or older
- FDA approved 2013
- Implantation
  - Device within the skull
  - Combination of 1-2 depths or subdural strips over seizure focus
- Closed loop
- Stimulation usually does not cause appreciable symptoms
- Stores ECoG
- Seizure detections algorithms programmed





# RNS Stimulation Parameters

- Five sequential stimulations
  - Rapid succession
  - Each two bursts
- Starting 1mA
  - Adjust up to  $3\mu\text{C}/\text{cm}^2/\text{phase}$
- Pulse width 160 $\mu\text{s}$
- Frequency 200 Hz
- Burst duration 100ms
- Polarity of electrodes can be configured
  - Close bipolar within electrode (+-- and +-+)
  - Wide bipolar across electrode (+++ and ----)
  - From electrode to generator cover

# The RNS® System

## The First Closed-Loop, Brain-Responsive Neurostimulation System




- Frequency, timing, and location of electrographic activity
- Over months/years in a naturalistic setting

# Responsive Neurostimulation

Personalized for each individual's seizure fingerprint


## Step 1: Detection

Physician identifies and programs neurostimulator to detect patient-specific electrocorticographic patterns.




## Step 2: Stimulation


Physician programs device to automatically stimulate in response to specific patterns, with the goal of preventing a clinical seizure.



# Pivotal Study: Mean Disabling Seizures




# Pre-specified Subset Analyses (Randomization Characteristics)



# Prospective Outcomes at Year 9

**75% median seizure reduction at year 9**



**73% achieved  $\geq 50\%$  seizure reduction at year 9**


**35% achieved  $\geq 90\%$  seizure reduction in most recent 6 months**

**28% had at least 1 period of  $\geq 6$  months without seizures**

Long-Term Treatment Trial was not powered to drive conclusions of clinical significance.

# Seizure Freedom

- Approximately 1 in 4 patients (28%) had at least 1 seizure-free period of  $\geq 6$  months
- Approximately 1 in 6 patients (18%) had at least 1 seizure-free period of  $\geq 1$  year



Nair et al., *submitted*

# Neuropsychological Benefits


[Loring DW et al., *Epilepsia*, 2015]

- No group decline on any of 14 objective neuropsychological measures after blinded period or at 1 and 2 years (n=175)
- Statistically significant<sup>1</sup> improvements in:
  - **Naming** (BNT; p<0.001)
  - **Verbal learning** (AVLT; p=0.03)
  - **Visual memory** (BVMT-R total recall; p=0.03)
  - **Executive function** [D-KEFS design fluency (p<0.001), WAIS-III Block design (p<0.001); WAIS-III Information (p=0.009)]

<sup>1</sup> GEE


# Quality of Life Improvements

[Heck CN et al., *Epilepsia*, 2014]



Outcomes reported at 2 years, n=191

# Statistically significant reduction in SUDEP in patients treated with the RNS System



\*TRE = Treatment Resistant Epilepsy

\*\*RNS System data represents SUDEP rate per 1000 stimulation years.


<sup>1</sup> Ryvlin P, Cucherat M, Rheims S; Lancet Neurol. 2011; 10:961–8.

<sup>2</sup> Dasheiff, R.M., 1991. J Clin Neurophysiol 8, 216–222.

<sup>3</sup> Devinsky O, Friedman D, et al. Epilepsia. 2018; 1-7.

# SUDEP Rates

[Devinsky et al., *Epilepsia*. 2018: 1-7]



\*TRE = Treatment Resistant Epilepsy

\*\*RNS System data represents SUDEP rate per 1000 stimulation years for the combined clinical trial and post-trial real-world experience.

<sup>1</sup> Ryvlin P, Cucherat M, Rheims S; Lancet Neurol. 2011; 10:961-8.

<sup>2</sup> Dasheiff, R.M., 1991. J Clin Neurophysiol 8, 216-222.

<sup>3</sup> Devinsky O, Friedman D, et al. Epilepsia. 2018; 1-7.

# Long-term Safety

- Clinical trial experience represents 256 patients with >1,895 implant years
- Safety outcomes from prospective clinical trials
  - No adverse cognitive effects<sup>1</sup>
  - No adverse mood effects<sup>2</sup>
  - No chronic stimulation side effects<sup>3</sup>
  - Rate of serious adverse events comparable to that of deep brain stimulation for movement disorders and epilepsy.<sup>4,5†</sup>
  - Device-related hemorrhage in 3.5% of subjects<sup>6‡</sup>
- Infection risk 4.1% per neurostimulator procedure

1. Loring DW, et al, *Epilepsia*, 2015

2. Meador K, et al, *Epilepsy Behav*, 2015

3. Heck, CN, et al, *Epilepsia*. 2014

4. Morrell, MJ, et al, *Epilepsia*, 2011

5. Salanova V, et al, *Neurology*, 2015

6. Bergey, GK, et al, *Neurology*, 2015

† Based on device related SAEs


‡ Not seizure related

# Conclusions



- Safe and effective over 9 years of prospective follow-up
- Efficacy reaches 75% at 9 years; similar in all brain regions
- Candidates for the RNS System include patients with:
  - Bilateral mesial temporal onsets
  - Unilateral mesial temporal onset with risks to memory or language with resection
  - Onset in eloquent (functional) cortex
  - Suboptimal response to VNS or epilepsy surgery
- Ongoing post-approval study will provide additional prospective safety and effectiveness data in 300 patients

# Supplement Clinical Seizure Reports

- RNS System data can reveal trends in long episodes over time




# Multi-Day Rhythms Modulate Seizure Risk



# Lateralization of seizures of MTL onset


[King-Stephens et al., *Epilepsia*, 2015]



# Lateralization of seizures of MTL onset

[King-Stephens et al., *Epilepsia*, 2015]


In **20% of patients**, the presumed lateralization determined by prior diagnostic testing changed after chronic ambulatory ECoG monitoring.



11 patients presumed unilateral;  
7/11 (64%) had bilateral electrographic seizures

71 patients presumed bilateral,  
9/71 (13%) had only unilateral electrographic seizures


# Changes in interictal spikes may serve as early indicators of patient's clinical response to AEDs



Use interictal biomarkers as a treatment endpoint to iterate device settings and AEDs

# Life Style Modification

- Frequent episodes of status epilepticus (SE)
- Episodes of SE occurred only on weekends



**Figure.** (A) Example of Pattern A detection. (B) Example of Pattern B detection. (C) Mean number of epileptiform discharges during control period, shown in black, compared to abstinence period, shown in red. Statistical significance ( $p < 0.05$ ) shown in green asterisk.

Source: Mackow, M., et al. (2016) *Clinical Neurophysiology*, 127(6), 2341-2342.

# Long-term ECoG recordings with RNS® System may help identify resection candidates

Chronic unlimited recording electrocorticography-guided resective epilepsy surgery: technology-enabled enhanced fidelity in seizure focus localization with improved surgical efficacy

Clinical article

DANIEL J. DiLORENZO, M.D., PH.D., M.B.A.<sup>1</sup> ERWIN Z. MANGUBAT, M.D.,<sup>1</sup>  
MARVIN A. ROSSI, M.D., PH.D.,<sup>2</sup> AND RICHARD W. BYRNE, M.D.<sup>1</sup>

Departments of <sup>1</sup>Neurosurgery and <sup>2</sup>Neurology, Rush University Medical Center, Chicago, Illinois

Case Report

Complementary effect of surgical resection and responsive brain stimulation in the treatment of bitemporal lobe epilepsy: A case report

Rei Enatsu <sup>a</sup>, Andreas Alexopoulos <sup>a,b</sup>, William Bingaman <sup>a,c</sup>, Dileep Nair <sup>a,b,\*</sup>

<sup>a</sup> Epilepsy Center, Cleveland Clinic, Cleveland, OH, USA

<sup>b</sup> Department of Neurology, Cleveland Clinic, Cleveland, OH, USA

<sup>c</sup> Department of Neurosurgery, Cleveland Clinic, Cleveland, OH, USA

- Data obtained from the RNS System identified 4 patients who had not previously been considered for resective surgery as candidates.
- Patients subsequently underwent resective surgery
- All 4 are seizure free (2/4 continued w/ RNS System)
- RNS System data showed predominately right seizure onsets
- Right MTL resection and responsive stimulation on left, now seizure free

DiLorenzo, D. et al, *Journal of Neurosurgery*, 2014.

Enatsu, R et al, *Epilepsy & Behavior*, 2012.